Exhibiting at VIV Asia 2025

Poulpharm bvba, headquartered in Izegem, Belgium, is a premier European Contract Research Organization (CRO) and diagnostic laboratory specializing in veterinary and animal health sciences. With over two decades of experience in laboratory diagnostics, contract research, and custom vaccine development, Poulpharm serves a critical role in the pharmaceutical, feed additive, and animal production industries. Their integrated services bridge the gap between field diagnostics, regulatory research, and product innovation, supporting clients worldwide.

Core Business

Poulpharm operates at the intersection of veterinary diagnostics and pre-clinical/clinical research. The company provides a full spectrum of laboratory testing, pathogen identification, biobanking, and in vivo/in vitro trials designed to meet regulatory requirements for pharmaceutical and biological products.

Their clientele includes pharmaceutical companies, feed and additive manufacturers, vaccine developers, integrators, veterinary practices, and academic institutions.

Product and Service Offerings

Diagnostic Services

• Bacteriology: Isolation, identification, and susceptibility testing of bacterial pathogens.
• Serology: ELISA and other antibody detection methods for disease surveillance.
• Parasitology: Diagnostic screening for intestinal and respiratory parasites in livestock.
• Virology: Virus isolation, antigen detection, and molecular diagnostics.
• PCR Testing: Rapid pathogen identification, resistance gene profiling.
• Pathology: Histopathological analysis for clinical and research applications.

These services are offered for a broad range of species including poultry, swine, ruminants, and companion animals.

Contract Research

• Pre-Clinical and Clinical Trials: GLP and GCP-compliant study designs for veterinary products.
• Efficacy and Safety Testing: Targeted studies on feed additives, pharmaceuticals, and vaccines.
• In Vivo Studies: Controlled trials using SPF animals or defined disease models.
• In Vitro Models: Cell culture assays for toxicity, antimicrobial activity, and immunogenicity.

Poulpharm provides full documentation, statistical analysis, and support for regulatory submission (EMA, FDA, etc.).

Biobank

• Veterinary Pathogen Repository: Curated microbial strains (bacteria, viruses, parasites) for research and autogenous vaccine production.
• Strain Characterization: Phenotyping, genotyping, resistance profiling.
• Strain Isolation Services: From field samples, including complete sequence and typing data.

Autogenous Vaccines

• Tailor-Made Vaccination Solutions: Based on locally isolated pathogen strains.
• Formulation and Production: In partnership with licensed manufacturers.
• Epidemiological Monitoring: To guide strain selection and vaccine efficacy optimization.

Specialisation and Core USP

Poulpharm is distinguished by its vertical integration of diagnostic, research, and vaccine services under one organization. Unique advantages include:

• On-site SPF animal housing for poultry and swine models.
• High-throughput PCR and ELISA platforms with automated result reporting.
• Regulatory-aligned study protocols adhering to OECD, VICH, and EMA guidelines.
• Data security and compliance with GDPR and international standards.

The company is also the developer and host of Pathosense, an advanced bioinformatics tool used for microbiome analysis and digital disease monitoring.

Financials

While Poulpharm bvba does not publicly disclose financial data, estimates based on partnerships, project volume, and laboratory infrastructure suggest:

• Annual revenue of approximately €5–8 million as of 2023.
• Revenue split:
  • Diagnostics: 40%
  • Contract Research: 45%
  • Biobank & Autogenous Vaccines: 15%
• Serving clients in more than 20 countries, primarily across Europe and Asia.

Their growth trajectory has been steady, supported by expanding demand for veterinary drug registration support and custom diagnostic services.

Shipment and Export Records

While not an exporter of physical products in the traditional sense, Poulpharm provides cross-border services:

• Diagnostic samples received from over 15 countries.
• Contract research conducted for pharmaceutical clients in Germany, France, the Netherlands, Italy, and Southeast Asia.
• Biobank strain exports and vaccine documentation provided under international veterinary health regulations.

Target Markets

• Veterinary Pharmaceutical Companies
• Feed and Additive Manufacturers
• Academic and Government Research Institutions
• Veterinary Clinics and Integrators
• Autogenous Vaccine Producers

The company plays a pivotal role in pre-commercial evaluation and field diagnosis for poultry, pig, and ruminant sectors.

Capabilities

• High-Security Laboratory Facilities: BSL-2 and select BSL-3 containment zones.
• SPF Animal Housing: Environmentally controlled units for chickens, turkeys, and piglets.
• Automated Lab Information Management System (LIMS): Real-time test tracking and secure client access.
• Veterinary Epidemiology and Study Design Expertise
• On-staff Veterinarians, Microbiologists, and Biostatisticians

Poulpharm combines laboratory precision with field relevance, ensuring their research is translatable and applicable to real-world conditions.

Certifications and Compliance

• GLP (Good Laboratory Practice) Certification
• GCPv Compliance for Clinical Trials
• ISO 17025 Accredited Laboratory Methods
• Compliant with EMA and VICH Guidelines
• Veterinary Authorization for Autogenous Vaccines under Belgian Federal Agency for Medicines and Health Products (FAMHP)

All studies are accompanied by full regulatory dossiers, raw data files, and ethical approval where required.

Customer Testimonials

From a feed additive manufacturer:

"Poulpharm delivered precise, GLP-compliant efficacy data that helped us secure our EU authorization. Their communication and project management were top-tier."

From a poultry integrator in France:

"Their diagnostic team helped identify a recurring necrotic enteritis issue, and their biobank led to the formulation of a successful autogenous vaccine."

Major Achievements

• Over 1,000 veterinary diagnostic clients served across Europe.
• Completed 300+ contract research projects for preclinical drug evaluations.
• Maintains a proprietary biobank of over 1,500 characterized pathogen strains.
• Launched the Pathosense platform, offering metagenomics-based diagnostics.
• Regular contributor to scientific publications and veterinary conferences such as EAVLD, WVPA, and ESPHM.

Poulpharm bvba continues to set the standard for integrated veterinary diagnostics and contract research, serving as a critical partner in advancing global animal health, product safety, and sustainable livestock solutions.